Discover the latest advantages of using a personalized, tumor-informed circulating tumor DNA (ctDNA) test to design oncology clinical trials in solid tumors, and Breast Cancer in particular.  Learn how Signatera, a breakthrough technology, can be applied in early stage and late stage cancer trials, potentially enriching for patients most likely to respond to therapy, accelerating time to trial readout, or identifying early relapsers.  
Topics will include:

  • Latest data in Breast Cancer from 2020 publications and abstracts
  • Advantages of a personalized, tumor-informed ctDNA assay for molecular residual disease detection
  • Signatera clinical data in early and late stage Breast Cancer
  • Applications of Signatera in clinical trial design to maximize trial success, and accelerate time to data readout

Featured Speaker

Dr. Angel Augusto Rodriguez


Dr. Angel Augusto Rodriguez is a board certified medical oncologist who specializes in breast medical oncology and conducted clinical research with circulating tumor DNA. Before joining Natera, Dr. Rodriguez practiced at Austin Cancer Centers and Houston Methodist Cancer Center where he was Director of the Clinical Trials Office and the Triple Negative Breast Cancer Clinic.  While at Houston Methodist he was principal investigator of clinical trials and conducted clinical research with circulating tumor DNA.